Pomaglumetad methionil
Pomaglumetad methionil is a metabotropic glutamate mGlu2 and mGlu3 receptor agonist which is or was under development for the treatment of schizophrenia, substance-related disorders, and post-traumatic stress disorder. It is taken orally.
Pharmacology
The drug is an inactive prodrug of pomaglumetad, which acts as a highly selective metabotropic glutamate mGlu2 and mGlu3 receptor agonist. Whereas the oral bioavailability of pomaglumetad was found to be low in humans, pomaglumetad methionil has an estimated oral bioavailability of approximately 49%. The drug is transported by the peptide transporter 1, resulting in it being rapidly and efficiently absorbed, and is then hydrolyzed into pomaglumetad. The elimination half-life of pomaglumetad methionil is 1.5 to 2.4hours, whereas the half-life of pomaglumetad is 2 to 6.2hours.
Development
Pomaglumetad methionil was under development by Eli Lilly and Company, Denovo Biopharma, and other institutions. As of January 2025, no recent development has been reported for treatment of schizophrenia or substance-related disorders, whereas development has been discontinued for PTSD. The highest developmental stage that pomaglumetad methionil has reached is phase 2 clinical trials.